Employer Benefits Dictate Use of Weight-Loss Drugs, Survey Reveals

DALLAS, TX – April 07, 2026 – As breakthrough weight-loss medications like Wegovy and Zepbound reshape healthcare, a new national survey reveals that an employee's decision to use them hinges significantly on their employer's benefits package. The research highlights a complex interplay of cost, behavioral support, and social stigma that is defining the next chapter of obesity management in the American workplace.

A poll conducted by The Harris Poll on behalf of Wondr Health, a behavioral weight management company, found that a staggering 65% of employed adults would be more likely to use a GLP-1 medication if their employer covered at least part of the cost. This finding underscores the pivotal role companies now play in employee access to these transformative but expensive treatments.

“Weight-loss medications like Wegovy and Zepbound are often discussed in terms of drug costs, but our new data suggests employees view them as part of a broader approach to improving their health,” said Scott Paddock, CEO of Wondr Health, in a statement accompanying the results.

The Employer's Dilemma: Balancing Cost and Demand

The surging demand for GLP-1s has placed employers in a challenging position. On one hand, they face pressure from a workforce eager for effective weight management solutions. On the other, they must contend with the formidable price tag of these drugs, which can exceed $10,000 per employee annually and contribute to rising health insurance premiums.

Despite the cost, coverage is growing. Recent industry data shows a significant uptick, with one 2024 analysis from consulting firm Mercer indicating that 44% of employers with 500 or more workers now cover obesity drugs, up from 41% the previous year. For the largest corporations, that figure is closer to 64%.

To manage the financial impact, many employers and health plans are implementing strict prior authorization requirements. These measures often require documentation of a patient's BMI, a history of failed lifestyle modifications, and proof of obesity-related comorbidities before approving the prescription. This administrative layer aims to ensure the medications are used by those with the greatest medical need, but it can also create access hurdles for patients.

The Wondr Health survey suggests a long-term value proposition that may sway employers. Nearly two-thirds (63%) of employed adults said they would be willing to take a GLP-1 medication long-term if it helped them reduce or eliminate other medications used to manage chronic conditions like diabetes or hypertension. This points to a potential return on investment, where high upfront drug costs could be offset by future savings from a healthier, more productive workforce.

“Employers have an opportunity to shape how these treatments are used by pairing medication access with a lifestyle and behavioral program proven to help people lose weight, improve their health, and maintain these results over time,” Paddock noted.

Beyond the Pill: The Rise of Integrated Behavioral Support

The survey reveals that cost is not the only factor. A majority of employees (56%) said they would be more likely to pay for a GLP-1 medication out of pocket if their employer also offered a behavioral support program to help manage their weight loss journey.

This finding is critical, as it shows employees value a holistic approach over a simple prescription. Integrated support programs, which often combine GLP-1s with one-on-one coaching, nutrition counseling, and lifestyle guidance, are increasingly seen as the key to maximizing the drugs' effectiveness and ensuring long-term success. Clinical evidence supports this view, with studies showing that combining GLP-1 therapy with intensive lifestyle interventions leads to more significant and sustainable weight loss.

These programs help patients navigate common challenges that medication alone cannot solve. Coaches can provide strategies for managing side effects, a common reason for the high discontinuation rates seen with GLP-1s. They also help individuals build sustainable habits around nutrition and physical activity, which are crucial for maintaining weight loss if the medication is ever stopped. Furthermore, behavioral support can address the psychological aspects of eating and help preserve muscle mass during rapid weight loss, ensuring a healthier outcome.

The Social Factor: Stigma and the Path to Acceptance

Beyond the financial and medical considerations, the survey sheds light on a powerful social barrier: stigma. Nearly half of all Americans (49%) reported they would be more comfortable using GLP-1 medications if the treatments were more widely accepted by society. This feeling is particularly pronounced among certain demographics.

Men (53%) were more likely than women (45%) to say social acceptance would increase their comfort. The pressure appears most intense for mid-career professionals; 72% of employed adults aged 35-44 cited societal acceptance as a key factor, compared to their younger and older colleagues. Higher-income individuals also reported greater sensitivity to social perception.

This stigma often stems from a cultural narrative that views obesity as a personal failing rather than a complex chronic disease. Consequently, using medication for weight loss is sometimes mischaracterized as “cheating” or taking “the easy way out.”

“The expanding GLP-1 market allows us to move beyond a one-size-fits-all approach to obesity management,” said Dr. Tim Church, Chief Medical Officer of Wondr Health. “By understanding how these therapies work to address the biological drivers of obesity, we can reduce stigma and support more informed health decisions while providing comprehensive care options.”

As the GLP-1 market, valued at over $50 billion in 2024, continues its explosive growth, the conversation is shifting. The focus is moving from a simple debate over drug costs to a more nuanced understanding of how to build a comprehensive ecosystem of care. This includes fair and strategic insurance coverage, robust behavioral support, and a concerted effort to dismantle the social stigma that prevents individuals from seeking effective medical treatment for obesity. For millions of American workers, the path to better health may run directly through their employer's human resources department.